ESTRELLA IMMUNOPHARMA, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$1.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- ESTRELLA IMMUNOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $543.10K.
- ESTRELLA IMMUNOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$495.44K.
- ESTRELLA IMMUNOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-09-30 was -$2.37M, a 112.05% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$4.32M.
- ESTRELLA IMMUNOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $467.39K.
- ESTRELLA IMMUNOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $1.69M.
- ESTRELLA IMMUNOPHARMA, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$1.61M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.24M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $543.10K 10-Q · filed 2026-05-18 | |||
| 2025-12-31 | $467.39K 10-K · filed 2026-03-18 | |||
| 2025-09-30 | $709.69K 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $399.68K 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | -$495.44K 10-Q · filed 2026-05-18 | |||
| 2024-12-31 | -$3.25M 10-K · filed 2026-03-18 | |||
| 2024-09-30 | -$2.37M 10-Q · filed 2024-11-14 | -$7.25M 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | -$4.88M 10-Q · filed 2025-08-12 | $1.69M 10-KT · filed 2025-03-25 | ||
| 2024-03-31 | -$4.32M 10-Q · filed 2025-05-14 | $2.25M 10-Q · filed 2024-05-15 | ||
| 2023-12-31 | $6.57M 10-Q · filed 2024-02-14 | |||
| 2023-09-30 | $19.66M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$1.61M 10-K · filed 2024-09-27 | |||
| 2023-03-31 | -$1.43M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$1.21M 10-Q · filed 2024-02-14 | |||
| 2022-09-30 | -$1.10M 10-Q · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |